Since the FSA Public List of CBD products was published on 31 March there has been considerable media coverage regarding its content. Much of the… Read More »First FSA on-the-record comments on new CBD products
The UK has become the first country in the world to regulate the market for safe, orally consumed legal cannabis extracts, following the release today… Read More »World first for consumer cannabinoids as UK’s FSA releases list of permitted CBD products
ACI have opened a new Brussels office as we expand our membership offering into the European Union (EU) for the first time.
The Taskforce on Innovation, Growth and Regulatory Reform (TIGRR) has today reported its recommendations to the Prime Minister on how the UK can reshape regulation and seize new opportunities from Brexit.
ACI Launches Membership Package to Support Businesses to Enter The New Regulated Consumer Cannabinoid Markets
The Association for the Cannabinoid Industry (ACI) today announced an updated new membership offering to support companies who wish to enter the newly regulated UK… Read More »ACI Launches Membership Package to Support Businesses to Enter The New Regulated Consumer Cannabinoid Markets
Register now for our upcoming event on Wednesday 19th May to discuss and consider the findings and conclusions of our recent report – Green Shoots: Sowing the seeds of the new UK cannabinoid market
ACI and Centre for Medicinal Cannabis (CMC) today launch the report Green Shoots – Sowing The Seeds Of The New UK Cannabinoid Market with a new assessment of the size of the UK consumer cannabidiol (CBD) sector.
ACI Submits Response On Behalf of our Members to ACMD’s Call for Evidence on Cannabinoids in CBD Products
Following a consultation with our members ACI have compiled a response to the Advisory Council on the Misuse of Drugs’ (ACMD) recent call for evidence on cannabinoids in CBD products.
ACI today publicly rebuts the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
Experts from the Association for the Cannabinoid Industry (ACI) and Centre for Medicinal Cannabis (CMC) have put together a detailed safety review paper of THC – Health Guidance Levels for THC in CBD products: Safety Assessment & Regulatory Recommendations. The paper recommends further research and makes policy recommendations.